New COPD drug tested across chinese, japanese, and european volunteers
NCT ID NCT06979518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a single dose of the experimental drug GSK3862995B in 30 healthy adults of Chinese, Japanese, and European ancestry. The goal was to see if the drug is processed similarly across these groups, so that future global COPD studies can include diverse participants. Researchers monitored safety, side effects, and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GSK3862995B
What this could lead to
If successful, this study could help include Chinese and Japanese participants in future global trials for chronic obstructive pulmonary disease treatments.
What could go wrong
This is an early phase 1 safety study with only 30 healthy people, so it cannot yet show if the drug works for COPD. Results may not apply to patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Cypress, California, 90630, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89113, United States